logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
T

Tamar Safra

Tel Aviv University
H指数:33
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to ‘Cytoreductive surgery in advanced epithelial ovarian cancer: a real-world analysis guided by clinical variables, homologous recombination, and BRCA status’ [International Journal of Gynecological Cancer Volume 35 Issue 6 (2025) 101809]

勘误：‘Cytoreductive surgery in advanced epithelial ovarian cancer: a real-world analysis guided by clinical variables, homologous recombination, and BRCA status’ [International Journal of Gynecological Cancer Volume 35 Issue 6 (2025) 101809]

International Journal of Gynecological Cancer
IF4.7
2025-06-110
PRE
Eliya Shachar; Yael Raz; Gilat Rotkop; Uriel Katz; Ido Laskov; Nadav Michan; Dan Grisaru; Ido Wolf; Tamar Safra
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results

帕博利珠单抗在微卫星高度不稳定/错配修复缺陷（MSI-H/dMMR）和非微卫星高度不稳定/非错配修复缺陷（non-MSI-H/non-dMMR）晚期子宫内膜癌中的疗效：KEYNOTE-158研究II期结果

gynecologic oncology
IF4.1
2025-02-012
PRE
O'Malley, David M.; Bariani, Giovani M.; Cassier, Philippe A.; Marabelle, Aurelien; Hansen, Aaron R.; Acosta, Ana De Jesus; Miller Jr, Wilson H.; Safra, Tamar; Italiano, Antoine; Mileshkin, Linda; Yao, Lili; Gozma, Alexander; Jin, Fan; Maio, Michele
Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2024-09-280
OAAI
Auranen, Annika; Powell, Matthew A.; Sukhin, Vladyslav; Landrum, Lisa M.; Ronzino, Graziana; Buscema, Joseph; Bauerschlag, Dirk; Lalisang, Roy; Bender, David; Gilbert, Lucy; Armstrong, Amy; Safra, Tamar; Nevadunsky, Nicole; Sebastianelli, Alexandra; Slomovitz, Brian; Ring, Kari; Coleman, Robert; Podzielinski, Iwona; Stuckey, Ashley; Teneriello, Michael; Gill, Sarah; Pothuri, Bhavana; Willmott, Lyndsay; Sharma, Sudarshan; Dabrowski, Christine; Antony, Grace; Stevens, Shadi; Mirza, Mansoor Raza; Fleming, Evelyn
Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants
BREAST CANCER RESEARCH AND TREATMENT
IF3
2020-04-188
PREAI
Bernstein-Molho, Rinat; Friedman, Eitan; Kedar, Inbal; Laitman, Yael; Allweis, Tanir M.; Gal-Yam, Einav Nili; Feldman, Hagit Baris; Grinshpun, Albert; Halpern, Naama; Hartmajer, Shulamit; Kadouri, Luna; Katz, Lior H.; Kaufman, Bella; Laish, Ido; Levanon, Keren; Philipsborn, Shira Litz; Ludman, Mark; Moran, Gal; Peretz, Tamar; Reinstein, Eyal; Levi, Gili Reznick; Safra, Tamar; Shkedi, Shiri; Vinkler, Chana; Levy, Zohar; Goldberg, Yael
ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer
CANCER RESEARCH
IF16.6
2019-07-015
PRE
Westin, Shannon N.; Kristeleit, Rebecca S.; Coleman, Robert L.; Fujiwara, Keiichi; Oza, Amit M.; O'Malley, David M.; Herzog, Thomas J.; Marme, Frederik; Oaknin, Ana; Eskander, Ramez; Lorusso, Domenica; Safra, Tamar; Korach, Jacob; Lin, Kevin K.; Shih, Danny; Caunt, Lisa; Goble, Sandra; Hume, Stephanie; Maloney, Lara; McNeish, Iain; Monk, Bradley J.
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
BRITISH JOURNAL OF CANCER
IF6.8
2018-10-24147
OAAI
Friedlander, Michael; Matulonis, Ursula; Gourley, Charlie; du Bois, Andreas; Vergote, Ignace; Rustin, Gordon; Scott, Clare; Meier, Werner; Shapira-Frommer, Ronnie; Safra, Tamar; Matei, Daniela; Shirinkin, Vadim; Selle, Frederic; Fielding, Anitra; Lowe, Elizabeth S.; McMurtry, Emma L.; Spencer, Stuart; Rowe, Philip; Mann, Helen; Parry, David; Ledermann, Jonathan
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

铂敏感的复发性浆液性卵巢癌和BRCA突变患者的奥拉帕尼维持治疗: 根据进展后聚 (二磷酸腺苷核糖) 聚合酶抑制剂治疗调整的总生存期

CANCER
IF5.1
2016-04-0883
OAAI
Matulonis, Ursula A.; Harter, Philipp; Gourley, Charlie; Friedlander, Michael; Vergote, Ignace; Rustin, Gordon; Scott, Clare; Meier, Werner; Shapira-Frommer, Ronnie; Safra, Tamar; Matei, Daniela; Fielding, Anitra; Spencer, Stuart; Parry, David; Grinsted, Lynda; Ledermann, Jonathan A.

研究方向

暂未获取到该数据
I
Ido Wolf
H 指数:41论文数:420被引数:8,322
I
Ido Laskov
H 指数:18论文数:122被引数:919
D
Dan Grisaru
H 指数:33论文数:204被引数:3,797
E
Eliya Shachar
H 指数:7论文数:54被引数:353
F
Franco M. Muggia
H 指数:75论文数:790被引数:2.5万
N
Nadav Michaan
H 指数:13论文数:106被引数:509
R
Ronnie Shapira‐Frommer
H 指数:46论文数:293被引数:2.7万
J
Jonathan A. Ledermann
H 指数:89论文数:503被引数:4.9万
I
Ignace Vergote
H 指数:135论文数:1,882被引数:8.9万
C
Charlie Gourley
H 指数:60论文数:463被引数:2.4万